These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 3928283)

  • 1. Rifampicin for non-tuberculous infections?
    Grüneberg RN; Emmerson AM; Cremer AW
    Chemotherapy; 1985; 31(4):324-8. PubMed ID: 3928283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that rifampicin can be used safely for non-tuberculous diseases.
    Acocella G; Brumfitt W; Hamilton-Miller JM
    Thorax; 1980 Oct; 35(10):788-91. PubMed ID: 6781092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can rifampicin use be safely extended? Evidence for non-emergence of resistant strains of Mycobacterium tuberculosis.
    Acocella G; Hamilton-Miller JM; Brumfitt W
    Lancet; 1977 Apr; 1(8014):740-2. PubMed ID: 66530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of FASTPlaqueTB-RIF, a rapid, manual test for the determination of rifampicin resistance from Mycobacterium tuberculosis cultures.
    Albert H; Heydenrych A; Mole R; Trollip A; Blumberg L
    Int J Tuberc Lung Dis; 2001 Oct; 5(10):906-11. PubMed ID: 11605883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cross-resistance between rifampin and rifabutin in multidrug resistant Mycobacterium tuberculosis complex strains].
    Gao L; Xiao HP; Hu ZY; Cui ZL; Lu JM; Shen XN
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 May; 35(5):333-5. PubMed ID: 22883990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypically occult multidrug-resistant Mycobacterium tuberculosis: dilemmas in diagnosis and treatment.
    Ho J; Jelfs P; Sintchencko V
    J Antimicrob Chemother; 2013 Dec; 68(12):2915-20. PubMed ID: 23838950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early results from indirect drug susceptibility test for tubercle bacilli.
    Mathew S; Narayanan A; Segaran R; Paramasivan CN
    Indian J Med Res; 1999 May; 109():167-9. PubMed ID: 10643140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of mutations detected by INNO-LiPA with levels of rifampicin resistance in Mycobacterium tuberculosis.
    Srivastava K; Das R; Jakhmola P; Gupta P; Chauhan DS; Sharma VD; Singh HB; Sachan AS; Katoch VM
    Indian J Med Res; 2004 Aug; 120(2):100-5. PubMed ID: 15347859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.
    de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE
    Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rifampicin inhibitory titer in wild strains of Mycobacterium and Rifampicin serum concentrations in tuberculous patients].
    Hussels H; Schütz I
    Beitr Klin Erforsch Tuberk Lungenkr; 1969; 140(1):304-12. PubMed ID: 4980954
    [No Abstract]   [Full Text] [Related]  

  • 11. [Percentual content of Rifampicin-resistant mutants in the wild strains of tubercle bacilli isolated from patients untreated with rifampicin].
    Blitek-Golc D; Antosiewicz A; Zduńczyk-Pawelek H
    Gruzlica; 1972 Sep; 40(9):833-9. PubMed ID: 4631233
    [No Abstract]   [Full Text] [Related]  

  • 12. Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey.
    Senol G; Erbaycu A; Ozsöz A
    J Chemother; 2005 Aug; 17(4):380-4. PubMed ID: 16167516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Critical concentration for definition of rifampicin resistance of tubercle bacilli].
    Tsukamura M
    Kekkaku; 1972 May; 47(5):113-9. PubMed ID: 4625369
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of FASTPlaqueTB-RIF for determination of rifampicin resistance in Mycobacterium tuberculosis complex isolates.
    Kisa O; Albay A; Bedir O; Baylan O; Doganci L
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):284-8. PubMed ID: 12661845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies for the determination of clinically available criteria of resistance of tubercle bacilli to rifampicin.
    Gomi J; Yanagisawa K; Murohashi T
    Kekkaku; 1970 Oct; 45(10):317-22. PubMed ID: 4991063
    [No Abstract]   [Full Text] [Related]  

  • 16. [Survival of tuberculous bacilli in combined treatments including rifampicin].
    Kreis B; Pretet S
    Rev Tuberc Pneumol (Paris); 1970; 34(3):429-33. PubMed ID: 4994940
    [No Abstract]   [Full Text] [Related]  

  • 17. [The clinical significance of the critical drug concentration of rifampicin. Report 1. Studies on the MIC of rifampicin to tubercle bacilli isolated from the rifampicin untreated patients using 1% Ogawa medium (author's transl)].
    Baba H; Azuma Y
    Kekkaku; 1976 Jan; 51(1):1-5. PubMed ID: 815708
    [No Abstract]   [Full Text] [Related]  

  • 18. [Detection and characteristics of rpoB gene mutations in rifampicin-resistant clinical strains of M. tuberculosis].
    Generozov EV; Al'tshuler ML; Govorun VM; Lopukhin IuM; Golyshevskaia VI; Chernousova LN; Khomenko AG
    Probl Tuberk; 1999; (2):39-42. PubMed ID: 10420750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative studies on the influence of dimethylsulfoxide (DMSO) on reversion to sensitivity to isonicotinic acid hydrazide (INH) and rifampicin (RMP) in resistant strains of tubercle bacilli.
    Szydłowska T; Pawłowska I
    Arch Immunol Ther Exp (Warsz); 1976; 24(4):575-7. PubMed ID: 826230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive phenotypic characterization of rifampicin resistance mutations in Salmonella provides insight into the evolution of resistance in Mycobacterium tuberculosis.
    Brandis G; Pietsch F; Alemayehu R; Hughes D
    J Antimicrob Chemother; 2015 Mar; 70(3):680-5. PubMed ID: 25362573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.